Illumina Inc. Reports Decline in Q3 Profit, Surpassing Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Should l Buy ILMN?
Source: NASDAQ.COM
Third Quarter Earnings: Illumina Inc. reported a profit of $150 million, or $0.98 per share, for the third quarter, a decrease from $705 million, or $4.42 per share, in the same period last year, but still beating analyst expectations.
Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $206 million, or $1.34 per share, surpassing the average analyst estimate of $1.17 per share.
Revenue Growth: The company's revenue increased by 0.4% to $1.084 billion compared to $1.080 billion in the previous year.
Future Guidance: Illumina provided full-year EPS guidance in the range of $4.65 to $4.75.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to rise
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 118.940
Low
40.50
Averages
133.54
High
170.00
Current: 118.940
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Precision Medicine: The collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare efficiency.
- Personalized Health Services: Veritas' myGenome whole-genome sequencing service is designed to integrate into health insurer environments, enabling members to benefit from preventive genomics at a personalized level, facilitating earlier disease risk identification and tailored prevention strategies.
- Transforming Healthcare Models: The consortium aims to shift care from reactive treatment to proactive prevention by identifying risks in hereditary cancer, cardiometabolic diseases, and medication responses, further expanding the clinical utility of genomics and supporting scalable, evidence-based adoption across the healthcare ecosystem.
See More
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Health Management: This collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare quality.
- Personalized Prevention Strategies: Through the myGenome whole-genome sequencing service, members can benefit from preventive genomics at a personalized level, enabling earlier disease risk identification and improving long-term health outcomes, thus shifting care from reactive treatment to proactive prevention.
- Industry Collaboration Opportunities: The consortium aims to create an integrated clinical-genomics dataset to facilitate industry partnerships in precision medicine, helping identify elevated risks in hereditary cancer, cardiometabolic diseases, and medication responses, further advancing the clinical utility of genomics.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes by adding 50,000 additional whole genomes paired with proteomic data, significantly enhancing the depth and breadth of clinical data to support drug discovery.
- Multiomic Integration: GSK, as one of the first participants, drives the multiomic expansion of AGD by utilizing Illumina's Protein Prep technology, which adds molecular depth to the dataset aimed at accelerating target discovery and therapy development, thereby improving drug development efficiency.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating impactful research in areas such as autoimmune diseases and obesity, showcasing its significant clinical application value.
- Strengthened Partnerships: The addition of RGC not only expands the AGD database scale but also enhances collaboration with Illumina and the biopharma community, promoting the construction of large-scale population genomics and driving innovation and efficiency in new drug development.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes with the addition of Regeneron Genetics Center as the tenth member, significantly enhancing the depth and breadth of clinical data, thereby providing a stronger foundation for drug discovery.
- Multiomic Data Integration: GSK, as one of the first participants, drives the pairing of 50,000 whole genomes with proteomic data, aimed at accelerating target discovery and therapy development, thus improving the efficiency and precision of drug research.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating research advancements in areas such as autoimmune diseases and obesity, thereby fostering innovation in drug development.
- Strengthened Partnerships: Through collaboration with Illumina and Regeneron, AGD plans to continue expanding its database, leveraging large-scale human genomic data to drive the discovery of new drug targets and enhance the efficiency and effectiveness of clinical R&D.
See More
Illumina Advances Rare Disease Diagnostics with New Lab Partnership
- Clinical Genome Sequencing Adoption: Illumina announced that its CLIA-certified laboratory is providing clinical sequencing and interpretation services to the Florida State University Pediatric Rare Diseases Diagnostic Lab, which is expected to significantly enhance diagnostic capabilities for 15 million American children affected by rare diseases, helping to break diagnostic barriers.
- Widespread Impact of Rare Diseases: Currently, approximately 30 million people in the U.S. live with rare diseases, and Illumina's whole-genome testing offers a transformative opportunity for patients, aiming to reduce the time from diagnosis to clinical management, thereby improving health outcomes.
- Laboratory Technological Innovation: The IPRD Diagnostic Lab utilized services from Illumina's Customer Success and Implementation team to rapidly initiate clinical diagnostic testing, marking a technological advancement in handling clinical samples and enhancing the lab's ability to address complex diseases.
- Significant Health Impact: Scientific Director Cynthia Vied noted that the new workflows not only impact the health of patients and families but also assist physicians in developing treatment plans based on the diagnostic results provided by the lab, highlighting the importance of genomic technology in clinical applications.
See More
Illumina Advances Diagnostics for Rare Diseases with New Lab Partnership
- Clinical Genome Sequencing Adoption: Illumina announced that its CLIA-certified laboratory is providing clinical sequencing and interpretation services to the Florida State University Pediatric Rare Diseases Diagnostic Lab, which is expected to significantly enhance diagnostic capabilities for 15 million American children affected by rare diseases, driving innovation in healthcare.
- Breaking Diagnostic Barriers: Dr. Eric Green, Illumina's Chief Medical Officer, emphasized that clinical whole-genome testing offers a transformative opportunity for 30 million people living with rare diseases, enabling physicians to more swiftly identify and manage previously unencountered conditions, thereby improving patient health outcomes.
- Laboratory Collaboration Enhances Efficiency: The IPRD Diagnostic Lab utilized services from Illumina's Customer Success and Implementation team to rapidly initiate clinical diagnostic testing, indicating a deepening of their long-standing partnership, which aids in accelerating the transition from diagnosis to clinical management.
- Mission for Human Health: Illumina is committed to improving human health by unlocking the power of the genome, supporting customers like IPRD in finding answers for patients with rare genetic diseases, thereby reinforcing its leadership position in the life sciences sector.
See More
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Precision Medicine: The collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare efficiency.
- Personalized Health Services: Veritas' myGenome whole-genome sequencing service is designed to integrate into health insurer environments, enabling members to benefit from preventive genomics at a personalized level, facilitating earlier disease risk identification and tailored prevention strategies.
- Transforming Healthcare Models: The consortium aims to shift care from reactive treatment to proactive prevention by identifying risks in hereditary cancer, cardiometabolic diseases, and medication responses, further expanding the clinical utility of genomics and supporting scalable, evidence-based adoption across the healthcare ecosystem.
See More
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Health Management: This collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare quality.
- Personalized Prevention Strategies: Through the myGenome whole-genome sequencing service, members can benefit from preventive genomics at a personalized level, enabling earlier disease risk identification and improving long-term health outcomes, thus shifting care from reactive treatment to proactive prevention.
- Industry Collaboration Opportunities: The consortium aims to create an integrated clinical-genomics dataset to facilitate industry partnerships in precision medicine, helping identify elevated risks in hereditary cancer, cardiometabolic diseases, and medication responses, further advancing the clinical utility of genomics.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes by adding 50,000 additional whole genomes paired with proteomic data, significantly enhancing the depth and breadth of clinical data to support drug discovery.
- Multiomic Integration: GSK, as one of the first participants, drives the multiomic expansion of AGD by utilizing Illumina's Protein Prep technology, which adds molecular depth to the dataset aimed at accelerating target discovery and therapy development, thereby improving drug development efficiency.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating impactful research in areas such as autoimmune diseases and obesity, showcasing its significant clinical application value.
- Strengthened Partnerships: The addition of RGC not only expands the AGD database scale but also enhances collaboration with Illumina and the biopharma community, promoting the construction of large-scale population genomics and driving innovation and efficiency in new drug development.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes with the addition of Regeneron Genetics Center as the tenth member, significantly enhancing the depth and breadth of clinical data, thereby providing a stronger foundation for drug discovery.
- Multiomic Data Integration: GSK, as one of the first participants, drives the pairing of 50,000 whole genomes with proteomic data, aimed at accelerating target discovery and therapy development, thus improving the efficiency and precision of drug research.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating research advancements in areas such as autoimmune diseases and obesity, thereby fostering innovation in drug development.
- Strengthened Partnerships: Through collaboration with Illumina and Regeneron, AGD plans to continue expanding its database, leveraging large-scale human genomic data to drive the discovery of new drug targets and enhance the efficiency and effectiveness of clinical R&D.
See More
Illumina Advances Rare Disease Diagnostics with New Lab Partnership
- Clinical Genome Sequencing Adoption: Illumina announced that its CLIA-certified laboratory is providing clinical sequencing and interpretation services to the Florida State University Pediatric Rare Diseases Diagnostic Lab, which is expected to significantly enhance diagnostic capabilities for 15 million American children affected by rare diseases, helping to break diagnostic barriers.
- Widespread Impact of Rare Diseases: Currently, approximately 30 million people in the U.S. live with rare diseases, and Illumina's whole-genome testing offers a transformative opportunity for patients, aiming to reduce the time from diagnosis to clinical management, thereby improving health outcomes.
- Laboratory Technological Innovation: The IPRD Diagnostic Lab utilized services from Illumina's Customer Success and Implementation team to rapidly initiate clinical diagnostic testing, marking a technological advancement in handling clinical samples and enhancing the lab's ability to address complex diseases.
- Significant Health Impact: Scientific Director Cynthia Vied noted that the new workflows not only impact the health of patients and families but also assist physicians in developing treatment plans based on the diagnostic results provided by the lab, highlighting the importance of genomic technology in clinical applications.
See More
Illumina Advances Diagnostics for Rare Diseases with New Lab Partnership
- Clinical Genome Sequencing Adoption: Illumina announced that its CLIA-certified laboratory is providing clinical sequencing and interpretation services to the Florida State University Pediatric Rare Diseases Diagnostic Lab, which is expected to significantly enhance diagnostic capabilities for 15 million American children affected by rare diseases, driving innovation in healthcare.
- Breaking Diagnostic Barriers: Dr. Eric Green, Illumina's Chief Medical Officer, emphasized that clinical whole-genome testing offers a transformative opportunity for 30 million people living with rare diseases, enabling physicians to more swiftly identify and manage previously unencountered conditions, thereby improving patient health outcomes.
- Laboratory Collaboration Enhances Efficiency: The IPRD Diagnostic Lab utilized services from Illumina's Customer Success and Implementation team to rapidly initiate clinical diagnostic testing, indicating a deepening of their long-standing partnership, which aids in accelerating the transition from diagnosis to clinical management.
- Mission for Human Health: Illumina is committed to improving human health by unlocking the power of the genome, supporting customers like IPRD in finding answers for patients with rare genetic diseases, thereby reinforcing its leadership position in the life sciences sector.
See More
